Display options
Cite
Chao TC, Pan WC, Tsai YF, et al. Corrigendum to "Plasma endoxifen and 4-hydroxytamoxifen levels in CYP2D6(C100T) carrying breast cancer patients and association with serum cholesterol" [Toxicology and Applied Pharmacology, 378 (2019) 114619]. Toxicol Appl Pharmacol. 2019;380:114701doi: 10.1016/j.taap.2019.114701.
Chao, T. C., Pan, W. C., Tsai, Y. F., Chou, Y. C., Liu, Y. R., Wang, S. F., Chen, Y. J., Souček, P., & Ueng, Y. F. (2019). Corrigendum to "Plasma endoxifen and 4-hydroxytamoxifen levels in CYP2D6(C100T) carrying breast cancer patients and association with serum cholesterol" [Toxicology and Applied Pharmacology, 378 (2019) 114619]. Toxicology and applied pharmacology, 380114701. https://doi.org/10.1016/j.taap.2019.114701
Chao, Ta-Chung, et al. "Corrigendum to "Plasma endoxifen and 4-hydroxytamoxifen levels in CYP2D6(C100T) carrying breast cancer patients and association with serum cholesterol" [Toxicology and Applied Pharmacology, 378 (2019) 114619]." Toxicology and applied pharmacology vol. 380 (2019): 114701. doi: https://doi.org/10.1016/j.taap.2019.114701
Chao TC, Pan WC, Tsai YF, Chou YC, Liu YR, Wang SF, Chen YJ, Souček P, Ueng YF. Corrigendum to "Plasma endoxifen and 4-hydroxytamoxifen levels in CYP2D6(C100T) carrying breast cancer patients and association with serum cholesterol" [Toxicology and Applied Pharmacology, 378 (2019) 114619]. Toxicol Appl Pharmacol. 2019 Oct 01;380:114701. doi: 10.1016/j.taap.2019.114701. Epub 2019 Aug 06. PMID: 31398422.
Copy Download .nbib Format: NLM
Share it on

Toxicol Appl Pharmacol. 2019 Oct 01;380:114701. doi: 10.1016/j.taap.2019.114701. Epub 2019 Aug 06.

Corrigendum to "Plasma endoxifen and 4-hydroxytamoxifen levels in CYP2D6(C100T) carrying breast cancer patients and association with serum cholesterol" [Toxicology and Applied Pharmacology, 378 (2019) 114619].

Toxicology and applied pharmacology

Ta-Chung Chao, Wen-Chi Pan, Yi-Fang Tsai, Yueh-Ching Chou, Yu-Rong Liu, Sheng-Fan Wang, Ying-Jen Chen, Pavel Souček, Yune-Fang Ueng

Affiliations

  1. Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.
  2. Institute of Environmental and Occupational Health Sciences, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
  3. Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.
  4. Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan; Department and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
  5. National Research Institute of Chinese Medicine, Taipei, Taiwan.
  6. Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan.
  7. Division of General Internal Medicine and Geriatrics, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan; Chang Gung University College of Medicine, Taoyuan City, Taiwan.
  8. Department of Toxicogenomics, National Institute of Public Health, Prague, Czech Republic.
  9. National Research Institute of Chinese Medicine, Taipei, Taiwan; Department and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei, Taiwan; Institute of Biopharmaceutical Sciences, School of Pharmacy, National Yang-Ming University, Taipei, Taiwan; Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan. Electronic address: [email protected].

PMID: 31398422 DOI: 10.1016/j.taap.2019.114701

[No abstract available.]

Publication Types